C57BL/6JCya-Dll3em1flox/Cya
Common Name:
Dll3-flox
Product ID:
S-CKO-02049
Background:
C57BL/6JCya
Product Type
Age
Genotype
Sex
Quantity
Price:
Contact for Pricing
Basic Information
Strain Name
Dll3-flox
Strain ID
CKOCMP-13389-Dll3-B6J-VA
Gene Name
Product ID
S-CKO-02049
Gene Alias
pu; pudgy
Background
C57BL/6JCya
NCBI ID
Modification
Conditional knockout
Chromosome
7
Phenotype
Document
Application
--
Note: When using this mouse strain in a publication, please cite “C57BL/6JCya-Dll3em1flox/Cya mice (Catalog S-CKO-02049) were purchased from Cyagen.”
Strain Description
Ensembl Number
ENSMUST00000108315
NCBI RefSeq
NM_007866
Target Region
Exon 3
Size of Effective Region
~1.3 kb
Detailed Document
Overview of Gene Research
Dll3, short for Delta-like ligand 3, is an inhibitory Notch ligand. The Notch signaling pathway is crucial in cell fate determination, development, and tissue homeostasis, and Dll3's role as an inhibitory ligand within this pathway is significant in regulating these processes [1,2,5,6].
Small cell lung cancer (SCLC) is an aggressive malignancy with limited treatment options. Dll3 is highly expressed in SCLC and other neuroendocrine tumors, but minimally in normal tissues [1,2,5]. Targeted therapies against Dll3 are being developed. For example, the antibody-drug conjugate rovalpituzumab tesirine, the bispecific T cell engager tarlatamab (AMG 757), and the chimeric antigen receptor T cell therapy AMG 119. Tarlatamab has shown manageable safety and encouraging response durability in patients with relapsed/refractory SCLC [1,3,5,6]. Also, IL-18-secreting CAR T cells targeting Dll3 display antitumor efficacy in SCLC models [4].
In conclusion, Dll3's role as an inhibitory Notch ligand is vital in biological regulation. Its overexpression in SCLC and other neuroendocrine tumors makes it a promising therapeutic target. The development of Dll3-targeted therapies offers new hope for treating these aggressive cancers, and further research on Dll3-related mechanisms may lead to more effective treatment strategies [1-4,7,9].
References：
1. Owen, Dwight H, Giffin, Michael J, Bailis, Julie M, Carbone, David P, He, Kai. 2019. DLL3: an emerging target in small cell lung cancer. In Journal of hematology & oncology, 12, 61. doi:10.1186/s13045-019-0745-2. https://pubmed.ncbi.nlm.nih.gov/31215500/
2. Yao, James, Bergsland, Emily, Aggarwal, Rahul, Umejiego, John, Pavel, Marianne. . DLL3 as an Emerging Target for the Treatment of Neuroendocrine Neoplasms. In The oncologist, 27, 940-951. doi:10.1093/oncolo/oyac161. https://pubmed.ncbi.nlm.nih.gov/35983951/
3. Paz-Ares, Luis, Champiat, Stephane, Lai, W Victoria, Hashemi Sadraei, Nooshin, Owonikoko, Taofeek K. 2023. Tarlatamab, a First-in-Class DLL3-Targeted Bispecific T-Cell Engager, in Recurrent Small-Cell Lung Cancer: An Open-Label, Phase I Study. In Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 41, 2893-2903. doi:10.1200/JCO.22.02823. https://pubmed.ncbi.nlm.nih.gov/36689692/
4. Jaspers, Janneke E, Khan, Jonathan F, Godfrey, William D, Rudin, Charles M, Brentjens, Renier J. 2023. IL-18-secreting CAR T cells targeting DLL3 are highly effective in small cell lung cancer models. In The Journal of clinical investigation, 133, . doi:10.1172/JCI166028. https://pubmed.ncbi.nlm.nih.gov/36951942/
5. Rudin, Charles M, Reck, Martin, Johnson, Melissa L, Umejiego, John, Paz-Ares, Luis. 2023. Emerging therapies targeting the delta-like ligand 3 (DLL3) in small cell lung cancer. In Journal of hematology & oncology, 16, 66. doi:10.1186/s13045-023-01464-y. https://pubmed.ncbi.nlm.nih.gov/37355629/
6. Su, Po-Lan, Chakravarthy, Karthik, Furuya, Naoki, Li, Zihai, He, Kai. 2024. DLL3-guided therapies in small-cell lung cancer: from antibody-drug conjugate to precision immunotherapy and radioimmunotherapy. In Molecular cancer, 23, 97. doi:10.1186/s12943-024-02012-z. https://pubmed.ncbi.nlm.nih.gov/38730427/
Quality Control Standard
Sperm Test
Pre-cryopreservation: Measurement of sperm concentration, determination of sperm viability.
Post-cryopreservation: A vial of cryopreserved sperms is selected for in-vitro fertilization from each batch.
Environmental Standards:SPF
Available Region:Global
Source:Cyagen